Characterization of human tissue factor (TF)-specific monoclonal antibodies prepared using a rapid immunization protocol

Hybridoma

Volumn 24, Issue 2, 2005, Pages 78-85

  Chen, Chaoyuan ^a   Yang, Qifeng ^a   Patel, Sima ^a   Lei, Ying ^a   McAleer, Lihong ^a   Singleton, Judith ^a   Soltis, Daniel ^a   Wang, Baiyang ^a,b  

^a PURDUE PHARMA L P   (United States)

^b BioRexis Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; THROMBOPLASTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SYNTHESIS; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNIZATION; MODIFIED REPETITIVE IMMUNIZATION AT MULTIPLE SITE PROTOCOL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 20344389278     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2005.24.78     Document Type: Article

References (38)

1. Nemerson Y: Tissue factor and hemostasis. Blood 1988;71:1-8.
2. Drake TA, Morrissey JH, and Edgington TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-1097.
3. Wilcox JN, Smith KM, Schwartz SM, and Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-2843.
4. Callander NS, Varki N, and Rao LV: Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201.
5. Lykke J, and Nielsen HJ: The role of tissue factor in colorectal cancer. Eur J Surg Oncol 2003;29:417-422.
6. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, and Suzuki H: Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-898.
7. Akashi T, Furuya Y, Ohta S, and Fuse H: Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003 ;62:1078-1082.
8. Ohta S, Wada H, Nakazaki T, Maeda Y, Nobori T, Shiku H, Nakamura S, Nagakawa O, Furuya Y, and Fuse H: Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002;22:2991-2996.
9. Minamiya Y, Matsuzaki I, Sageshima M, Saito H, Taguchi K, Nakagawa T, and Ogawa J: Expression of tissue factor mRNA and invasion of blood vessels by tumor cells in non-small cell lung cancer. Surg Today 2004;34:1-5.
10. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, and Yoshizawa Y: Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999;79:472-477.
11. Contrino J, Hair G, Kreutzer DL, and Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-215.
12. Koomagi R, and Volm M: Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79:19-22.
13. Mueller BM, Reisfeld RA, Edgington TS, and Ruf W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832-11836.
14. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, and Garen A: Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209.
15. Hu Z, Sun Y, and Garen A: Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999;96:8161-8166.
16. Hu Z, and Garen A: Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA 2000;97:9221-9225.
17. Hu Z, and Garen A: Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001;98:12180-12185.
18. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, and McIntyre GD: Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 1997;16:381-389.
19. Morrissey JH, Fair DS, and Edgington TS: Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988;52:247-261.
20. Fang CH, Lin TC, Guha A, Nemerson Y, and Konigsberg WH: Activation of factor X by factor VIIa complexed with human-mouse tissue factor chimeras requires human exon 3. Thromb Haemost 1996;76:361-368.
21. Kohler G, and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
22. Borrebaeck CA: In vitro immunization for the production of antigen-specific lymphocyte hybridomas. Scand J Immunol 1983;18:9-12.
23. Winter G, and Milstein C: Man-made antibodies. Nature 1991;349:293-299.
24. Holley MC: A simple in vitro method for raising monoclonal antibodies to cochlear proteins. Tissue Cell 1992;24:613-624.
25. Steenbakkers PG, van Meel FC, and Olijve W: A new approach to the generation of human or murine antibody producing hybridomas. J Immunol Methods 1992;152:69-77.
26. Caterson B, Christner JE, and Baker JR: Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulfate. J Biol Chem 1983;258:8848-8854.
27. Orlik O, and Altaner C: Modifications of hybridoma technology which improve the yield of monoclonal antibody producing cells. J Immunol Methods 1988;115:55-59.
28. Berek C, Berger A, and Apel M: Maturation of the immune response in germinal centers. Cell 1991;67:1121-1129.
29. MacLennan IC: Germinal centers. Annu Rev Immunol 1994;12:117-139.
30. Kelsoe G: Life and death in germinal centers (redux). Immunity 1996;4:107-111.
31. Levy NS, Malipiero UV, Lebecque SG, and Gearhart PJ: Early onset of somatic mutations in immunoglobulin VH genes during the primary immune response. J Exp Med 1989;169:2007-2019.
32. Kinch MS, Kilpatrick KE, and Zhong C: Identification of tyrosine phosphorylated adhesion proteins in human cancer cells. Hybridoma 1998;17:227-235.
33. Wring SA, Kilpatrick KE, Hutchins JT, Witherspoon SM, Ellis B, Jenner WN, and Serabjit-Singh C: Shorter development of immunoassay for drugs: application of the novel RIMMS technique enables rapid production of monoclonal antibodies to ranitidine. J Pharm Biomed Anal 1999;19:695-707.
34. Bynum J, Andrews JL, Ellis B, Kull FC Jr, Austin EA, and Kilpatrick KE: Development of class-switched, affinity-matured monoclonal antibodies following a 7-day immunization schedule. Hybridoma 1999;18:407-411.
35. Lindley KM, Su JL, Hodges PK, Wisely GB, Bledsoe RK, Condreay JP, Winegar DA, Hutchins JT, and Kost TA: Production of monoclonal antibodies using recombinant baculovirus displaying gp64-fusion proteins. J Immunol Methods 2000;234:123-135.
36. Kilpatrick KE, Cutler T, Whitehorn E, Drape RJ, Macklin MD, Witherspoon SM, Singer S, and Hutchins JT: Gene gun delivered DNA-based immunizations mediate rapid production of murine monoclonal antibodies to the Flt-3 receptor. Hybridoma 1998;17:569-576.
37. Kilpatrick KE, Danger DP, Hull-Ryde EA, and Dallas W: High-affinity monoclonal antibodies to PED/PEA-15 generated using 5 jug of DNA. Hybridoma 2000;19:297-302.
38. Kilpatrick KE, Kerner S, Dixon EP, Hutchins JT, Parham JH, Condreay JP, and Pahel G: In vivo expression of a GST-fusion protein mediates the rapid generation of affinity matured monoclonal antibodies using DNA-based immunizations. Hybrid Hybridomics 2002;21:237-243.